Toxicological Potential of the FDA-Approved Treatment against Monkeypox. Comment on Zovi et al. Pharmacological Agents with Antiviral Activity against Monkeypox Infection. Int. J. Mol. Sci. 2022, 23, 15941

Journal of International Translational Medicine Pub Date : 2023-03-27 DOI:10.3390/ijtm3020013

Gabriel Christian de Farias Morais, U. L. Fulco, E. D. da Silva, C. B. S. Oliveira, J. I. N. Oliveira

{"title":"Toxicological Potential of the FDA-Approved Treatment against Monkeypox. Comment on Zovi et al. Pharmacological Agents with Antiviral Activity against Monkeypox Infection. Int. J. Mol. Sci. 2022, 23, 15941","authors":"Gabriel Christian de Farias Morais, U. L. Fulco, E. D. da Silva, C. B. S. Oliveira, J. I. N. Oliveira","doi":"10.3390/ijtm3020013","DOIUrl":null,"url":null,"abstract":"Recently, some drugs were approved to control Monkeypox (MPX), among them tecovirimat. This was recently approved by regulatory agencies around the world, the paper of Zovi et al entitled Pharmacological Agents with Antiviral Activity against Monkeypox Infection highlight it as safe and effective, although the safety data are still not very robust. In this Comment, we present some theoretical evaluations of its safety, considering that for use in humans it is essential to have a rich scientific literature in the area. After a series of analyses, a potential risk of liver, respiratory and kidney damage was found in addition to carcinogenic potential. Thus, while we agree that there is a need for rapid responses to infection, we reinforce that well-designed and adequately powered studies should not only focus on investigating the pharmacological efficacy of tecovirimat but also demonstrate its safety in humans. Therefore, in this Comment, we present some concerns that may help in formulating a safer treatment for patients infected with Monkeypox virus (MPXV).","PeriodicalId":43005,"journal":{"name":"Journal of International Translational Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of International Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/ijtm3020013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Recently, some drugs were approved to control Monkeypox (MPX), among them tecovirimat. This was recently approved by regulatory agencies around the world, the paper of Zovi et al entitled Pharmacological Agents with Antiviral Activity against Monkeypox Infection highlight it as safe and effective, although the safety data are still not very robust. In this Comment, we present some theoretical evaluations of its safety, considering that for use in humans it is essential to have a rich scientific literature in the area. After a series of analyses, a potential risk of liver, respiratory and kidney damage was found in addition to carcinogenic potential. Thus, while we agree that there is a need for rapid responses to infection, we reinforce that well-designed and adequately powered studies should not only focus on investigating the pharmacological efficacy of tecovirimat but also demonstrate its safety in humans. Therefore, in this Comment, we present some concerns that may help in formulating a safer treatment for patients infected with Monkeypox virus (MPXV).

查看原文本刊更多论文

fda批准的猴痘治疗的毒理学潜力。评论Zovi等人。具有抗猴痘感染抗病毒活性的药物。Int。生物医学工程学报，2002,23 (3):941 - 941

近年来，一些药物被批准用于控制猴痘(MPX)，其中包括替可韦莫。该药物最近得到了世界各地监管机构的批准，Zovi等人发表的题为《具有抗猴痘感染抗病毒活性的药理制剂》的论文强调了它的安全性和有效性，尽管安全性数据仍然不是很可靠。在这篇评论中，我们提出了一些关于其安全性的理论评估，考虑到在人类中使用它是必要的，在该领域有丰富的科学文献。经过一系列分析，除了潜在的致癌性外，还发现了对肝脏、呼吸系统和肾脏造成损害的潜在风险。因此，虽然我们同意有必要对感染做出快速反应，但我们强调，设计良好且有充分动力的研究不仅应关注研究tecovirimat的药理学功效，还应证明其在人体中的安全性。因此，在这篇评论中，我们提出了一些可能有助于制定更安全的猴痘病毒(MPXV)患者治疗方法的关注。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of International Translational Medicine MEDICINE, RESEARCH & EXPERIMENTAL-

自引率

0.00%

发文量

317

审稿时长

8 weeks

期刊介绍： Journal of International Translational Medicine (JITM, ISSN 2227-6394), founded in 2012, is an English academic journal published by Journal of International Translational Medicine Co., Ltd and sponsored by International Fderation of Translational Medicine. JITM is an open access journal freely serving to submit, review, publish, read and download full text and quote. JITM is a quarterly publication with the first issue published in March, 2013, and all articles published in English are compiled and edited by professional graphic designers according to the international compiling and editing standard. All members of the JITM Editorial Board are the famous international specialists in the field of translational medicine who come from twenty different countries and areas such as USA, Britain, France, Germany and so on.